Alzheimer’s prevention research is moving towards earlier diagnosis and intervention, as blood tests, disease-modifying drugs and pre-symptom clinical trials reshape dementia research.
LONDON: Alzheimer’s prevention research is entering a new phase as scientists increasingly focus on detecting biological changes earlier, slowing disease progression and testing whether treatment before symptoms appear could delay cognitive impairment. The shift is highlighted by the World Alzheimer Report 2026, released by Alzheimer’s Disease International as researchers explore new approaches to diagnosis and treatment.
The change marks an important departure from decades in which treatment largely concentrated on managing symptoms after memory and thinking problems had become apparent.
Researchers now have better tools for identifying biological signs associated with Alzheimer’s, while clinical trials are increasingly involving people at earlier stages of disease. ADI says there are currently 158 drugs being investigated across 192 dementia trials.
Why earlier detection matters
One important development is the emergence of increasingly accurate blood-based biomarkers. These tests could make it easier to identify Alzheimer’s-related biological changes without relying solely on more complex testing methods.
Earlier detection is becoming particularly relevant because newer disease-modifying medicines target underlying disease processes rather than simply treating symptoms.
Lecanemab and donanemab, for example, target amyloid deposits in the brain and have demonstrated modest slowing of clinical decline in people with early Alzheimer’s disease. They are not cures, can carry important risks and monitoring requirements, and are not suitable for everyone. Debate also continues over the magnitude of their clinical benefit.
Can Alzheimer’s eventually be prevented?
That remains one of the biggest unanswered questions.
Researchers are testing treatments in people who have biological signs associated with Alzheimer’s but have not yet developed symptoms. The aim is to discover whether intervening earlier can delay or potentially prevent cognitive impairment.
Alzheimer’s prevention research also extends beyond medicines. Updated World Health Organization guidance emphasises a life-course approach to reducing dementia risk, including healthy behaviours, management of associated health conditions and reducing exposure to relevant environmental risk factors.
These approaches reduce risk rather than guarantee that an individual will avoid Alzheimer’s.
The scale of the challenge remains considerable. The World Alzheimer Report notes that dementia research is entering a new era, but clinical trials still face challenges around recruitment, accessibility, diversity and ensuring that emerging treatments reach the people most likely to benefit.
For Alzheimer’s prevention research, the direction is increasingly clear: scientists want to identify disease processes sooner and intervene before irreversible damage becomes extensive. Whether today’s experimental preventive approaches can achieve that goal will depend on evidence from ongoing trials.
Impact to expect
Hope. Earlier diagnosis and disease-modifying treatments could gradually change Alzheimer’s care from reacting to advanced symptoms towards identifying risk and treating disease at an earlier stage.
